ACE and Hypertension: ,92 Whether CCS patients with prognostically relevant major periprocedural myocardial injury, who are not already on ACE-inhibitors (for heart failure, hypertension, or diabetes) or beta-blockers (for left ventricular dysfunction or systolic heart failure), would benefit from the addition of beta-blockers or ACE-inhibitors to reduce the risk of future MACE is not known, and needs to be further evaluated.